Brubru
EU policy intelligence
Regulation (EC) No 1901/2006 ended decades of off-label prescribing for children by creating an obligations-and-rewards bargain: every new medicine must be studied in children via a Paediatric Investigation Plan, and companies earn a six-month patent extension in return. Applied from 26 July 2008.
market forces alone have proven insufficient -- the obligations-and-rewards bargain that changed paediatric medicine
Before the Paediatric Regulation entered application in 2008, children across Europe were routinely treated with medicines that had never been tested in them. Recital 2 of the Regulation is blunt: "market forces alone have proven insufficient" to incentivise pharmaceutical companies to develop and test medicines specifically for paediatric patients. Companies had little commercial reason to run clinical trials in children; adults were a larger, simpler market. The result was that prescribers were forced to extrapolate doses from adult data, use unlicensed formulations or rely on medicines developed decades earlier.
The Regulation's response was not to regulate by prohibition alone but to create a system of obligations matched to rewards (recital 6): any company seeking a marketing authorisation for a new medicine must include paediatric study results or a granted waiver or deferral. In exchange, completing the agreed paediatric research programme earns a commercially significant patent-term incentive.
The Regulation rests on Article 95 TEC (internal market, equivalent to Article 114 TFEU after Lisbon), adopted by co-decision under Article 251 TEC. It was adopted at Strasbourg on 12 December 2006, signed by EP President Josep Borrell Fontelles and Council President Mauri Pekkarinen (Finnish Presidency), and published in OJ L 378 on 27 December 2006. It entered into force on the thirtieth day after publication, with the core marketing-authorisation obligation (Article 7) applying from 26 July 2008 and the existing-product obligation (Article 8) from 26 January 2009.
The Regulation amended four instruments simultaneously: the SPC Regulation (EEC) No 1768/92 (subsequently codified as Regulation (EC) No 469/2009), the Clinical Trials Directive 2001/20/EC, the Community code on medicinal products for human use (Directive 2001/83/EC), and the EMA Regulation (EC) No 726/2004.
The Regulation is cited here as adopted in 2006. Key developments since adoption:
The seven pillars of the Regulation: from PDCO creation to patent rewards
Articles 1-6: establishing the Paediatric Committee within the EMA by 26 July 2007
The Regulation applies to children from birth to 18 years. The breadth of this definition is deliberate: it covers neonates, infants, toddlers, children and adolescents, recognising that each sub-group may require different formulations, dosing regimens and pharmacokinetic studies. The Paediatric Investigation Plan must specify which paediatric age subsets are covered and by what methods.
A Paediatric Investigation Plan (PIP) is an R&D programme that specifies the timing and measures proposed to generate data on the use of a medicine in the paediatric population, including the age subsets to be studied, the formulation work required, the relevant clinical endpoints, and the schedule of studies agreed with the PDCO. A PIP may also include a request for a deferral or a waiver for one or more subsets.
The Regulation establishes the Paediatric Committee (PDCO) within the European Medicines Agency (EMA) by 26 July 2007 (Article 3). Its composition is set by Article 4: five members appointed from among the members and alternates of the Committee for Medicinal Products for Human Use (CHMP), one member from each otherwise-unrepresented Member State, three representatives of health-professional organisations, and three representatives of patient associations for paediatric medicines -- making it explicitly multi-stakeholder.
The PDCO's tasks (Article 6) include: assessing PIP applications and granting or refusing agreement; agreeing waivers (product-specific and class-level); agreeing deferrals; checking compliance with agreed PIPs; providing scientific advice free of charge (Article 26); and maintaining and updating the inventory of therapeutic needs (Article 43). PDCO opinions are adopted within 60 days of receipt of a valid application (Articles 13, 17), with a further 60 days if modifications are requested and a 30-day re-examination procedure (Article 25). PDCO assessments -- PIPs, waivers, deferrals, compliance checks -- are free of charge (Article 47).
Articles 7-26: the obligation, waivers, the Paediatric Investigation Plan, deferrals, compliance and free scientific advice
Article 7 creates the central obligation: an application for a marketing authorisation for a new medicinal product must include, as a component of the application, either:
Article 8 extends the obligation to applications for new indications, pharmaceutical forms and routes of administration of medicines that are still covered by a supplementary protection certificate or a patent qualifying for an SPC. This means even an established medicine seeking an additional indication must go through the PIP process if it still has patent protection.
Article 9 sets out the exemptions: the obligation does NOT apply to generic medicinal products, biosimilar products, well-established-use products, homeopathic products or herbal medicinal products.
The PDCO may grant a waiver, exempting a product from the PIP obligation, where the condition for which it is intended does not occur in children (adult-only disease), or where the product is likely to be ineffective or unsafe in children, or where the product does not represent a significant therapeutic benefit over existing treatments for children. Waivers may be product-specific or class-based (Article 11).
If a waiver is revoked -- because new evidence emerges that the product could be used in children -- the holder has a 36-month grace period before the obligation re-applies (Article 14(3)).
A deferral postpones the initiation or completion of paediatric studies to a time after the adult authorisation is completed. Its purpose is to ensure that research in children is not delayed simply because adult studies are still ongoing -- it separates the paediatric R&D timeline from the adult one without blocking adult authorisation. Deferrals are granted by the PDCO on the basis of the agreed PIP.
The PIP itself must be submitted no later than the completion of adult pharmacokinetic studies (Article 16), and PIP modification procedures are set out in Article 22.
At the point of a marketing authorisation application, the EMA or competent authority checks whether the agreed PIP has been complied with. Non-compliance means the application cannot proceed until compliance is established (Article 23). Where non-compliance is identified after authorisation, the holder is given the opportunity to remedy the situation, failing which Member States must impose proportionate penalties (Article 49). Scientific advice on the design of PIPs is free of charge for applicants (Article 26), reflecting the Regulation's intent to lower the barrier to paediatric research.
Articles 27-32: PUMA for off-patent products and the labelling symbol
The PUMA (Article 2(4)) is a dedicated marketing authorisation for off-patent medicinal products that are developed exclusively for paediatric use. This fills the gap left by the main obligation, which only applies to new products and patent-protected products: without the PUMA, off-patent generics would have no incentive to invest in paediatric development.
A PUMA may retain the same brand name as the adult version of the product (Article 30(4)), reducing the confusion caused by using a wholly different name for what is essentially the same active substance in a paediatric formulation. The PUMA earns the data and marketing protection of Article 14(11) of Regulation (EC) No 726/2004 (the "8+2+1" exclusivity framework applicable to centrally authorised products), providing a meaningful commercial incentive for off-patent development (Article 38 -- see Title V below).
Article 32 required the Commission to study the feasibility of a recognisable symbol to appear on the labelling of medicines that have paediatric indications or are suitable for paediatric use, and to adopt implementing measures if a suitable symbol was found.
In 2008 the Commission concluded that no symbol could be designed that would be sufficiently clear and non-misleading across the EU's linguistic and regulatory diversity. The labelling-symbol obligation accordingly became inoperative in practice, and no paediatric symbol was ever introduced in EU pharmaceutical labelling. This is noted here as a current-state flag.
Articles 27 to 29 regulate how paediatric studies and PIP results feed into the various EU marketing authorisation procedures: the centralised procedure under Regulation (EC) No 726/2004, the mutual recognition procedure, the decentralised procedure and national procedures. The CHMP evaluates paediatric data as part of its assessment under the centralised procedure; for national procedures, the competent authority of the reference Member State carries out the same function. The key rule is that the PIP compliance check is a prerequisite for the authorisation itself, not an optional add-on.
Articles 33-35: the 2-year marketing obligation, pharmacovigilance and supply continuity
Once a paediatric indication is authorised for an already-marketed medicine, the marketing authorisation holder must place it on the market within 2 years in all Member States where the adult version is authorised. This prevents companies from completing PIP studies, gaining the patent reward, and then simply not making the paediatric product available. It closes the gap between paper authorisation and actual market access for children.
Holders of marketing authorisations that include paediatric indications must ensure their pharmacovigilance systems cover the paediatric use of the product, including the risk management plan. Periodic safety update reports must specifically address paediatric outcomes. This ensures that safety monitoring does not stop once the PIP studies are complete and the reward is collected.
If a marketing authorisation holder that holds a paediatric indication wishes to withdraw from the market, it must notify the competent authority at least one year before withdrawal. The competent authority may transfer the authorisation to a third party willing to maintain supply, to ensure continuity of access to a medicine that children may depend on.
Articles 36-40: the three patent rewards and their conditions
All three rewards are conditional on completing the agreed PIP (not merely initiating it) and on ensuring that the results of the paediatric studies are reflected in the authorised product information. The SPC extension (Reward 1) additionally requires that the product be authorised in all Member States before the certificate can be extended. No reward is available to a product that obtained a waiver on the grounds that the medicine is irrelevant to children.
Beyond the three patent rewards, the Regulation provides for Community research funding and incentives for studies of existing off-patent medicines that do not qualify for a PUMA (Article 40), to address the therapeutic needs of children where commercial incentives are absent. This acknowledges that the PIP obligation and patent rewards solve the problem for new and patent-protected products but leave a residual gap for older, generic molecules where there is genuine unmet paediatric medical need.
Articles 41-46: the paediatric clinical trials database, therapeutic needs inventory and Enpr-EMA
The EMA maintains a publicly accessible European database of paediatric clinical trials, including trials conducted under PIPs and paediatric-only studies regardless of whether they result in a marketing authorisation. This transparency obligation ensures that the research actually conducted on children is recorded and accessible, reducing duplication and supporting data-sharing among researchers.
The PDCO maintains an inventory of the existing therapeutic needs of the paediatric population, listing the areas where research is most needed. This inventory is publicly available and regularly updated. It serves as a planning document for both the Commission's research-funding priorities and for companies deciding where to invest in PIP development. Areas of high unmet need identified in the inventory include paediatric oncology and neonatal intensive care.
Article 44 establishes the European Network of Paediatric Research at the EMA, now known as Enpr-EMA. This network connects academic paediatric clinical research centres, national networks and other expert bodies across Europe, enabling multi-centre paediatric trials, sharing of reference data and pooling of investigator expertise. Enpr-EMA plays a key role in making PIPs deliverable, particularly for rare paediatric conditions where no single centre can recruit sufficient patients alone.
Articles 47-57: fees, penalties, reporting, and the four amendments
All PDCO assessments -- Paediatric Investigation Plans, waivers, deferrals, compliance checks -- are free of charge. Scientific advice under Article 26 is also free. This is a deliberate policy choice: by removing fee barriers, the Regulation ensures that no company can use cost as an excuse not to engage with the PDCO. It also reflects the public-interest nature of paediatric research: the EU absorbs the EMA's assessment costs as part of the obligations-and-rewards bargain.
Member States must lay down rules on penalties for infringements of the Regulation and ensure they are applied. Penalties must be effective, proportionate and dissuasive. The most significant enforcement mechanism is non-compliance with an agreed PIP: a marketing authorisation application that does not include PIP results or a granted waiver/deferral is simply invalid and cannot proceed, which is itself the primary deterrent.
The Regulation sets two specific reporting deadlines:
Articles 52-55 amended the four cross-referenced instruments simultaneously with the adoption of the Paediatric Regulation:
Essential terms from Article 2 of Regulation (EC) No 1901/2006
The main procedural numbers from the Regulation
| Mechanism | Article | Key figure / deadline | Note |
|---|---|---|---|
| MA obligation (new products) | Art 7 | From 26 July 2008 | PIP results or waiver/deferral mandatory in every new MA application |
| MA obligation (existing patent-protected) | Art 8 | From 26 January 2009 | New indications, pharmaceutical forms, routes for SPC-covered products |
| PDCO opinion deadline | Arts 13, 17 | 60 days | +60 days if modifications requested; re-examination within 30 days (Art 25) |
| PIP submission timing | Art 16 | No later than completion of adult PK studies | Ensures paediatric planning starts early in development |
| Waiver revocation grace period | Art 14(3) | 36 months | Before the obligation re-applies after a waiver is revoked |
| Reward 1: SPC extension | Art 36 | 6 months | On completing agreed PIP; not available to orphans; requires all-MS authorisation |
| Reward 2: orphan exclusivity | Art 37 | 10 to 12 years | +2 years stacked on standard 10-year orphan exclusivity (Reg 141/2000) |
| Reward 3: PUMA exclusivity | Art 38 | 8+2+1 | Data + marketing + indication extension; for off-patent products only |
| 2-year marketing obligation | Art 33 | 2 years | After paediatric indication authorised; prevents reward-then-withdraw strategy |
| PDCO established by | Art 3 | 26 July 2007 | One year before the obligation applied; transition period for EMA set-up |
| PDCO assessments (fees) | Art 47 | Free | PIPs, waivers, deferrals, compliance checks and scientific advice all free |
| 10-year report | Art 50(3) | COM(2017)626 | Found positive results but gaps in oncology and rare paediatric diseases |
Key abbreviations and instruments referenced in the Paediatric Medicines Regulation
From adoption in 2006 to the provisional reform agreement in 2025
Primary documentation for Regulation (EC) No 1901/2006
Six tools to analyse, track and work with EU pharmaceutical legislation